Sandoz has introduced first-of-its-kind Tyruko® (natalizumab-sztn) biosimilar designed specifically for the treatment of relapsing forms of multiple sclerosis.
Tyruko is the first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis. Tyruko has been developed to exhibit a remarkably close resemblance to the reference medication, which happens to be a well-established and highly efficient disease-modifying treatment for relapsing forms of multiple sclerosis
This reference medicine is an anti-α4 integrin monoclonal antibody, recognised for its effectiveness in managing the condition.
In the United States, Tyruko has received approval for use as a standalone therapy to treat various forms of multiple sclerosis, encompassing clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), and active secondary progressive disease. Furthermore, it is also indicated for the treatment of Crohn’s disease in adult patients.
Tyruko closely mirrors the reference medicine in terms of its intravenous (IV) dosage form, route of administration, dosing regimen, and presentation.
Biosimilars are an important treatment option as they have no clinically meaningful differences from their reference medicines. Prescribing biosimilars enhances access to affordable medications, improves adherence, and contributes to controlling healthcare costs.